Thirty-seven percent is the number to hold onto. That is the share of women in AbCellera's Phase 2 who went from roughly ten moderate-to-severe hot flashes a day to none at all — four weeks after a single subcutaneous injection, with no further dosing . In a symptomatic indication where the approved therapies are daily pills that shave the frequency by rather less, complete suppression in better than a third of patients is not an incremental result. It is the kind of result that changes what a company is.
AbCellera spent most of the last decade as a Vancouver antibody-discovery shop: it mined immune repertoires, found antibodies against hard targets for pharmaceutical partners, and collected research fees, milestones and royalties. That model produced real money once — a COVID-19 neutralizing antibody royalty stream that has long since run off — and it has been shrinking ever since. In September 2023 management redirected the machine inward. Three years later the redirection is complete in the only sense that matters to a shareholder: at a $3.33 billion market capitalization and a $10.89 last close on September 11, up from a $2.75 fifty-two-week low , essentially all of the equity value sits in one wholly-owned molecule called ABCL635. My argument is that the next several months favor the owner of that molecule — not because the terminal valuation is cheap, but because the specific information arriving between now and mid-2027 is unusually likely to resolve in the drug's favor, and the company no longer needs the market's permission to get there.
From 35 partner-led programs to one wholly-owned antibody
AbCellera reports as a single operating segment , which is accurate as accounting and misleading as description, because four distinguishable businesses sit inside it. The first is the internal clinical pipeline — ABCL635 in Phase 2 for vasomotor symptoms, ABCL575 in Phase 1 in immunology and inflammation , with ABCL688 and ABCL386 expected to enter Phase 1/2 studies in 2027 . The second is a T-cell-engager discovery franchise that has just been validated commercially: Jazz Pharmaceuticals paid $56.0 million upfront in June for two programs with a further $28.0 million due on a third , and Vertex paid $28.0 million in July for autoimmune multispecifics , tripling deferred revenue to $61.2 million at June 30...